Double-Punch cancer trial tests vaccine & immune boosters
NCT ID NCT02955290
Summary
This study is testing whether combining a cancer vaccine (CIMAvax) with immunotherapy drugs (nivolumab or pembrolizumab) is safe and effective for people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to help the body's immune system better attack the cancer and control its growth. The trial involves about 51 participants and is designed to find the best dose and see how well the combination works to improve survival and slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Good Samaritan Hospital
West Islip, New York, 11795, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
St. Francis Hospital
Roslyn, New York, 11576, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.